Vantage Financial Partners Ltd. Inc. bought a new stake in Biogen Inc. (NASDAQ:BIIB) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 515 shares of the biotechnology company’s stock, valued at approximately $515,000.

Several other large investors also recently added to or reduced their stakes in BIIB. BlackRock Inc. increased its position in shares of Biogen by 2,762.0% in the first quarter. BlackRock Inc. now owns 17,692,259 shares of the biotechnology company’s stock valued at $4,837,418,000 after acquiring an additional 17,074,075 shares during the last quarter. Janus Capital Management LLC increased its position in shares of Biogen by 204.8% in the first quarter. Janus Capital Management LLC now owns 1,936,719 shares of the biotechnology company’s stock valued at $529,524,000 after acquiring an additional 1,301,251 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Biogen by 2,288.0% in the first quarter. Massachusetts Financial Services Co. MA now owns 1,352,164 shares of the biotechnology company’s stock valued at $369,709,000 after acquiring an additional 1,295,540 shares during the last quarter. Winslow Capital Management LLC acquired a new stake in shares of Biogen in the first quarter valued at about $345,143,000. Finally, Manning & Napier Advisors LLC increased its position in shares of Biogen by 563.8% in the second quarter. Manning & Napier Advisors LLC now owns 814,369 shares of the biotechnology company’s stock valued at $220,986,000 after acquiring an additional 691,694 shares during the last quarter. 87.65% of the stock is currently owned by institutional investors and hedge funds.

A number of analysts recently issued reports on the company. UBS AG raised Biogen from a “sell” rating to a “neutral” rating and lifted their target price for the company from $262.00 to $270.00 in a research report on Monday, June 19th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $307.00 target price on shares of Biogen in a research report on Wednesday, June 14th. Leerink Swann reissued a “market perform” rating and set a $338.00 price target (up previously from $304.00) on shares of Biogen in a research report on Wednesday, July 26th. Vetr downgraded Biogen from a “buy” rating to a “hold” rating and set a $298.30 price target on the stock. in a research report on Wednesday, July 26th. Finally, Goldman Sachs Group, Inc. (The) raised Biogen from a “buy” rating to a “conviction-buy” rating and set a $338.00 price target on the stock in a research report on Wednesday, August 16th. Thirteen equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company. Biogen has an average rating of “Buy” and a consensus price target of $331.53.

In other Biogen news, EVP Susan H. Alexander sold 4,974 shares of the firm’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $290.01, for a total value of $1,442,509.74. Following the completion of the transaction, the executive vice president now directly owns 22,258 shares of the company’s stock, valued at approximately $6,455,042.58. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Susan H. Alexander sold 7,758 shares of the firm’s stock in a transaction on Wednesday, July 19th. The shares were sold at an average price of $285.00, for a total transaction of $2,211,030.00. Following the completion of the transaction, the executive vice president now directly owns 27,232 shares of the company’s stock, valued at $7,761,120. The disclosure for this sale can be found here. 0.32% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: “515 Shares in Biogen Inc. (BIIB) Purchased by Vantage Financial Partners Ltd. Inc.” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.watchlistnews.com/515-shares-in-biogen-inc-biib-purchased-by-vantage-financial-partners-ltd-inc/1575131.html.

Shares of Biogen Inc. (NASDAQ:BIIB) opened at 317.93 on Wednesday. The firm’s 50-day moving average price is $300.47 and its 200 day moving average price is $278.47. The company has a market capitalization of $67.22 billion, a PE ratio of 20.86 and a beta of 0.77. Biogen Inc. has a 1-year low of $244.28 and a 1-year high of $330.00.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Tuesday, July 25th. The biotechnology company reported $5.04 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $4.36 by $0.68. Biogen had a net margin of 28.10% and a return on equity of 37.42%. The firm had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $2.81 billion. During the same period last year, the firm earned $5.21 EPS. The business’s quarterly revenue was up 6.4% compared to the same quarter last year. Equities analysts predict that Biogen Inc. will post $21.50 EPS for the current fiscal year.

About Biogen

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.